Abstract
Neuroinflammatory disorders such as multiple sclerosis (MS) encountered a therapeutic revolution in the last 20 years and have raised hope also for neurodegenerative diseases affecting especially the elderly population in western countries. Biomarkers, especially those from the field of neuroimaging, were decisive in accelerating drug development and optimization of treatments. Neuroimaging, however, may be not sufficient in the case of neurodegeneration, where structural alterations accumulate at a very low rate over several years. To capture this slow evolution, biomarkers in the cerebrospinal fluid appear as a very plausible candidate. We will review here, in general terms, the state of the art in the field biomarkers in the CSF with a special focus on the application of “omics” platforms.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Akers JC, Ramakrishnan V, Kim R et al (2013) miR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development. PLoS One 8:e78115. doi:10.1371/journal.pone.0078115.s009
Alcolea D, Carmona-Iragui M, Suárez-Calvet M et al (2014) Relationship between β-secretase. Inflammation and core cerebrospinal fluid biomarkers for Alzheimer’s disease. J Alzheimers Dis. doi:10.3233/JAD-140240
Alexandrov PN, Dua P, Hill JM et al (2012) microRNA (miRNA) speciation in Alzheimer’s disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF). Int J Biochem Mol Biol 3:365–373
Alves G, Lange J, Blennow K et al (2014) CSF Aβ42 predicts early-onset dementia in Parkinson disease. Neurology 82:1784–1790. doi:10.1212/WNL.0000000000000425
Baraniskin A, Kuhnhenn J, Schlegel U et al (2011a) Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood 117:3140–3146. doi:10.1182/blood-2010-09-308684
Baraniskin A, Kuhnhenn J, Schlegel U et al (2011b) Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. Neuro Oncol 14:29–33. doi:10.1093/neuonc/nor169
Barbariga M, Curnis F, Spitaleri A et al (2014) Oxidation-induced structural changes of ceruloplasmin foster NGR motif deamidation that promotes integrin binding and signaling. J Biol Chem 289:3736–3748. doi:10.1074/jbc.M113.520981
Bergink V, Gibney SM, Drexhage HA (2014) Autoimmunity, inflammation, and psychosis: a search for peripheral markers. Biol Psychiatry 75:324–331. doi:10.1016/j.biopsych.2013.09.037
Borgiani B, Colombo E, Furlan R (2012) Microvesicles: novel biomarkers for neurological disorders. Front Physiol 3:1–6. doi: 10.3389/fphys.2012.00063/abstract
Bossuyt PM, Reitsma JB, Bruns DE et al (2003) The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem 49:7–18
Cassol E, Misra V, Dutta A et al (2014) Cerebrospinal fluid metabolomics reveals altered waste clearance and accelerated aging in HIV patients with neurocognitive impairment. AIDS. doi:10.1097/QAD.0000000000000303
Castegna A, Thongboonkerd V, Klein JB et al (2003) Proteomic identification of nitrated proteins in Alzheimer’s disease brain. J Neurochem 85:1394–1401
Cech TR, Steitz JA (2014) The noncoding RNA revolution— trashing old rules to forge new ones. Cell 157:77–94. doi:10.1016/j.cell.2014.03.008
Chen X, Liang H, Zhang J et al (2012) Secreted microRNAs: a new form of intercellular communication. Trends Cell Biol 22:125–132. doi:10.1016/j.tcb.2011.12.001
Choi D-S, Kim D-K, Kim Y-K, Gho YS (2013a) Proteomics, transcriptomics and lipidomics of exosomes and ectosomes. Proteomics 13:1554–1571. doi:10.1002/pmic.201200329
Choi D-S, Lee J, Go G et al (2013b) Circulating extracellular vesicles in cancer diagnosis and monitoring: an appraisal of clinical potential. Mol Diagn Ther 17:265–271. doi:10.1007/s40291-013-0042-7
Cogswell JP, Ward J, Taylor IA et al (2008) Identification of miRNA changes in Alzheimer’s disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis 14:27–41
Conti A, Sanchez-Ruiz Y, Bachi A et al (2004) Proteome study of human cerebrospinal fluid following traumatic brain injury indicates fibrin(ogen) degradation products as trauma-associated markers. J Neurotrauma 21:854–863. doi:10.1089/0897715041526212
Conti A, Ricchiuto P, Iannaccone S et al (2005) Pigment epithelium-derived factor is differentially expressed in peripheral neuropathies. Proteomics 5:4558–4567. doi:10.1002/pmic.200402088
Conti A, Iannaccone S, Sferrazza B et al (2008) Differential expression of ceruloplasmin isoforms in the cerebrospinal fluid of amyotrophic lateral sclerosis patients. Proteomics Clin Appl 2:1628–1637. doi:10.1002/prca.200780081
Craft GE, Chen A, Nairn AC (2013) Recent advances in quantitative neuroproteomics. Methods 61:186–218. doi:10.1016/j.ymeth.2013.04.008
Cvjetkovic A, Lötvall J, Lässer C (2014) The influence of rotor type and centrifugation time on the yield and purity of extracellular vesicles. J Extracell Vesicles. doi:10.3402/jev.v3.23111
De Monte L, Sanvito F, Olivieri S et al (2008) Serological immunoreactivity against colon cancer proteome varies upon disease progression. J Proteome Res 7:504–514. doi:10.1021/pr070360m
Deregibus MC, Cantaluppi V, Calogero R et al (2007) Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood 110:2440–2448. doi:10.1182/blood-2007-03-078709
Dumurgier J, Laplanche J-L, Mouton-Liger F et al (2014) The screening of Alzheimer’s patients with CSF biomarkers, modulates the distribution of APOE genotype: impact on clinical trials. J Neurol 261:1187–1195. doi:10.1007/s00415-014-7335-6
Ferreira D, Perestelo-Pérez L, Westman E et al (2014) Meta-review of CSF core biomarkers in Alzheimer’s disease: the state-of-the-art after the new revised diagnostic criteria. Front Aging Neurosci 6:47. doi:10.3389/fnagi.2014.00047
Filippi M, Canu E, Agosta F (2013) The role of amyloid-β, tau, and apolipoprotein E epsilon4 in Alzheimer disease: how is the team playing? AJNR Am J Neuroradiol 34:511–512. doi:10.3174/ajnr.A3295
Fortea J, Vilaplana E, Alcolea D et al (2014) Cerebrospinal fluid β-amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease. Ann Neurol. doi:10.1002/ana.24186
Fraisier C, Papa A, Granjeaud S et al (2014) Cerebrospinal fluid biomarker candidates associated with human WNV neuroinvasive disease. PLoS One 9:e93637. doi:10.1371/journal.pone.0093637
Freedman MS, Thompson EJ, Deisenhammer F et al (2005) Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol 62:865–870. doi:10.1001/archneur.62.6.865
Freischmidt A, Ller KM, Ludolph AC, Weishaupt JH (2013) Systemic dysregulation of TDP-43 binding microRNAs in amyotrophic lateral sclerosis. Acta Neuropathol Commun 1(1):1. doi:10.1186/2051-5960-1-42
Frigerio CS, Lau P, Salta E et al (2013) Reduced expression of hsa-miR-27a-3p in CSF of patients with Alzheimer disease. Neurology 81:2103–2106
Galea I, Freedman MS, Thompson EJ (2011) Cerebrospinal fluid analysis in the 2010 revised McDonald’s multiple sclerosis diagnostic criteria. Ann Neurol 70:183. doi:10.1002/ana.22466, author reply 183–184
Gallego JA, Gordon ML, Claycomb K et al (2012) In vivo microRNA detection and quantitation in cerebrospinal fluid. J Mol Neurosci 47:243–248. doi:10.1007/s12031-012-9731-7
Garzetti L, Menon R, Finardi A et al (2013) Activated macrophages release microvesicles containing polarized M1 or M2 mRNAs. J Leukoc Biol. doi:10.1189/jlb.0913485
Haghikia A, Haghikia A, Hellwig K et al (2012) Regulated microRNAs in the CSF of patients with multiple sclerosis: a case–control study. Neurology 79:2166–2170. doi:10.1212/WNL.0b013e3182759621
Hjalmarsson C, Bjerke M, Andersson B et al (2014) Neuronal and glia-related biomarkers in cerebrospinal fluid of patients with acute ischemic stroke. J Cent Nerv Syst Dis 6:51–58. doi:10.4137/JCNSD.S13821
Hong BS, Cho J-H, Kim H et al (2009) Colorectal cancer cell-derived microvesicles are enriched in cell cycle-related mRNAs that promote proliferation of endothelial cells. BMC Genomics 10:556. doi:10.1186/1471-2164-10-556
Huang JT, Leweke FM, Tsang TM et al (2007a) CSF metabolic and proteomic profiles in patients prodromal for psychosis. PLoS One 2:e756. doi:10.1371/journal.pone.0000756
Huang JT, McKenna T, Hughes C et al (2007b) CSF biomarker discovery using label-free nano-LC-MS based proteomic profiling: technical aspects. J Sep Sci 30:214–225
Iannaccone S, Cerami C, Alessio M et al (2013) In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson’s disease. Parkinsonism Relat Disord 19:47–52. doi:10.1016/j.parkreldis.2012.07.002
Jakobsson J, Bjerke M, Ekman CJ et al (2014) Elevated concentrations of neurofilament light chain in the cerebrospinal fluid of bipolar disorder patients. Neuropsychopharmacology. doi:10.1038/npp.2014.81
Jarry J, Schadendorf D, Greenwood C et al (2014) ScienceDirect. Mol Oncol 8:819–829. doi:10.1016/j.molonc.2014.02.009
Kern S, Skoog I, Börjesson-Hanson A et al (2014) Higher CSF interleukin-6 and CSF interleukin-8 in current depression in older women. Results from a population-based sample. Brain Behav Immun. doi:10.1016/j.bbi.2014.05.006
Kiko T, Nakagawa K, Tsuduki T et al (2013) MicroRNAs in plasma and cerebrospinal fluid as potential markers for Alzheimer’s disease. J Alzheimers Dis 39:253–259. doi:10.3233/JAD-130932
Li G, Millard SP, Peskind ER et al (2014) Cross-sectional and longitudinal relationships between cerebrospinal fluid biomarkers and cognitive function in people without cognitive impairment from across the adult life span. JAMA Neurol 71:742–751. doi:10.1001/jamaneurol.2014.445
Lista S, Zetterberg H, Dubois B et al (2014) Cerebrospinal fluid analysis in Alzheimer’s disease: technical issues and future developments. J Neurol 261:1234–1243. doi:10.1007/s00415-014-7366-z
Liu Y, Qing H, Deng Y (2014) Biomarkers in Alzheimer’s disease analysis by mass spectrometry-based proteomics. Int J Mol Sci 15:7865–7882. doi:10.3390/ijms15057865
Lourenco AS, Baldeiras I, Graos M, Duarte CB (2011) Proteomics-based technologies in the discovery of biomarkers for multiple sclerosis in the cerebrospinal fluid. Curr Mol Med 11:326–349
Malek N, Swallow D, Grosset KA et al (2014) Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson’s disease – a systematic review. Acta Neurol Scand. doi:10.1111/ane.12247
Menon KN, Steer DL, Short M et al (2011) A novel unbiased proteomic approach to detect the reactivity of cerebrospinal fluid in neurological diseases. Mol Cell Proteomics 10(M110):000042. doi:10.1074/mcp.M110.000042
Müller M, Kuiperij HB, Claassen JA et al (2014) Neurobiology of aging. Neurobiol Aging 35:152–158. doi:10.1016/j.neurobiolaging.2013.07.005
Nakamura T, Tu S, Akhtar MW et al (2013) Aberrant protein s-nitrosylation in neurodegenerative diseases. Neuron 78:596–614. doi:10.1016/j.neuron.2013.05.005
Nazco CV, Pérez LP, Molinuevo JL et al (2014) Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer’s disease. J Alzheimers Dis. doi:10.3233/JAD-132216
Olivieri S, Conti A, Iannaccone S et al (2011) Ceruloplasmin oxidation, a feature of Parkinson’s disease CSF, inhibits ferroxidase activity and promotes cellular iron retention. J Neurosci 31:18568–18577. doi:10.1523/JNEUROSCI.3768-11.2011
Pacifici M, Delbue S, Ferrante P et al (2013) Cerebrospinal fluid miRNA profile in HIV-encephalitis. J Cell Physiol 228:1070–1075. doi:10.1002/jcp.24254
Palanisamy V, Sharma S, Deshpande A et al (2010) Nanostructural and transcriptomic analyses of human saliva derived exosomes. PLoS One 5:e8577. doi:10.1371/journal.pone.0008577
Parnetti L, Farotti L, Eusebi P et al (2014) Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson’s disease. Front Aging Neurosci 6:53. doi:10.3389/fnagi.2014.00053
Pegtel DM, van de Garde MDB, Middeldorp JM (2011) Viral miRNAs exploiting the endosomal-exosomal pathway for intercellular cross-talk and immune evasion. Biochim Biophys Acta 1809:715–721. doi:10.1016/j.bbagrm.2011.08.002
Perrin RJ, Payton JE, Malone JP et al (2013) Quantitative label-free proteomics for discovery of biomarkers in cerebrospinal fluid: assessment of technical and inter-individual variation. PLoS One 8:e64314. doi:10.1371/journal.pone.0064314
Plebani M, Sciacovelli L, Aita A et al (2014) Quality indicators to detect pre-analytical errors in laboratory testing. Clin Chim Acta 432:44–48. doi:10.1016/j.cca.2013.07.033
Pogue AI, Hill JM, Lukiw WJ (2014) MicroRNA (miRNA): sequence and stability, viroid-like properties, and disease association in the CNS. Brain Res 1584:73–9. doi: 10.1016/j.brainres.2014.03.042
Polman CH, Reingold SC, Banwell B et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292–302. doi:10.1002/ana.22366
Poulsen K, Bahl JM, Simonsen AH et al (2014) Distinct transthyretin oxidation isoform profile in spinal fluid from patients with Alzheimer’s disease and mild cognitive impairment. Clin Proteomics 11:12. doi:10.1186/1559-0275-11-12
Pouw MH, Kwon BK, Verbeek MM et al (2014) Structural biomarkers in the cerebrospinal fluid within 24 h after a traumatic spinal cord injury: a descriptive analysis of 16 subjects. Spinal Cord 52:428–433. doi:10.1038/sc.2014.26
Privitera D, Corti V, Alessio M et al (2013) Proteomic identification of aldolase A as an autoantibody target in patients with atypical movement disorders. Neurol Sci 34:313–320. doi:10.1007/s10072-012-0996-y
Rao P, Benito E, Fischer A (2013) MicroRNAs as biomarkers for CNS disease. Front Mol Neurosci 6:39. doi:10.3389/fnmol.2013.00039
Ratajczak J, Miekus K, Kucia M et al (2006) Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia 20:847–856. doi:10.1038/sj.leu.2404132
Ritchie C, Smailagic N, Noel-Storr AH et al (2014) Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 6:CD008782. doi: 10.1002/14651858.CD008782.pub4
Shan L (2011) CellVue Maroon–labeled saposin C-dioleylphosphatidylserine nanovesicles. Molecular Imaging and Contrast Agent Database (MICAD)
Siderowf A, Logroscino G (2014) β-Amyloid in CSF: a window into Parkinson disease dementia. Neurology 82:1758–1759. doi:10.1212/WNL.0000000000000437
Siritho S, Freedman MS (2009) The prognostic significance of cerebrospinal fluid in multiple sclerosis. J Neurol Sci 279:21–25. doi:10.1016/j.jns.2008.12.029
Skog J, Würdinger T, Van Rijn S et al (2008) Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10:1470–1476. doi:10.1038/ncb1800
Stoop MP, Coulier L, Rosenling T et al (2010a) Quantitative proteomics and metabolomics analysis of normal human cerebrospinal fluid samples. Mol Cell Proteomics 9:2063–2075. doi:10.1074/mcp.M900877-MCP200
Stoop MP, Singh V, Dekker LJ et al (2010b) Proteomics comparison of cerebrospinal fluid of relapsing remitting and primary progressive multiple sclerosis. PLoS One 5:e12442. doi:10.1371/journal.pone.0012442
Teplyuk NM, Mollenhauer B, Gabriely G et al (2012) MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro Oncol 14:689–700. doi:10.1093/neuonc/nos074
Teunissen CE, Petzold A, Bennett JL et al (2009) A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 73:1914–1922. doi:10.1212/WNL.0b013e3181c47cc2
Tortelli R, Copetti M, Ruggieri M et al (2014) Cerebrospinal fluid neurofilament light chain levels: marker of progression to generalized amyotrophic lateral sclerosis. Eur J Neurol. doi:10.1111/ene.12421
Tumani H, Hartung H-P, Hemmer B et al (2009) Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis 35:117–127. doi:10.1016/j.nbd.2009.04.010
Turner CA, Thompson RC, Bunney WE et al (2014) Altered choroid plexus gene expression in major depressive disorder. Front Hum Neurosci. doi:10.3389/fnhum.2014.00238/abstract
Valadi H, Ekström K, Bossios A et al (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9:654–659. doi:10.1038/ncb1596
van Gool AJ, Hendrickson RC (2012) The proteomic toolbox for studying cerebrospinal fluid. Expert Rev Proteomics 9:165–179. doi:10.1586/epr.12.6
Verderio C, Muzio L, Turola E et al (2012) Myeloid microvesicles are a marker and therapeutic target for neuroinflammation. Ann Neurol 72:610–624. doi:10.1002/ana.23627
Vranová HP, Hényková E, Kaiserová M, et al (2014) Tau protein, beta-amyloid1–42 and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia. J Neurol Sci 343:120–4. doi: 10.1016/j.jns.2014.05.052
Woods AG, Iosifescu DV, Darie CC (2014) Biomarkers in major depressive disorder: the role of mass spectrometry. Adv Exp Med Biol 806:545–560. doi:10.1007/978-3-319-06068-2_27
Yuan X, Desiderio DM (2003) Proteomics analysis of phosphotyrosyl-proteins in human lumbar cerebrospinal fluid. J Proteome Res 2:476–487
Yuan X, Desiderio DM (2005a) Proteomics analysis of human cerebrospinal fluid. J Chromatogr B Analyt Technol Biomed Life Sci 815:179–189. doi:10.1016/j.jchromb.2004.06.044
Yuan X, Desiderio DM (2005b) Human cerebrospinal fluid peptidomics. J Mass Spectrom 40:176–181. doi:10.1002/jms.737
Zhang J, Goodlett DR, Peskind ER et al (2005) Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid. Neurobiol Aging 26:207–227. doi:10.1016/j.neurobiolaging.2004.03.012
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Franciotta, D., Alessio, M., Garzetti, L., Furlan, R. (2015). Methods for Biomarker Analysis. In: Deisenhammer, F., Sellebjerg, F., Teunissen, C., Tumani, H. (eds) Cerebrospinal Fluid in Clinical Neurology. Springer, Cham. https://doi.org/10.1007/978-3-319-01225-4_13
Download citation
DOI: https://doi.org/10.1007/978-3-319-01225-4_13
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-01224-7
Online ISBN: 978-3-319-01225-4
eBook Packages: MedicineMedicine (R0)